Kathleen Tregoning Joins Compass Pathways Board of Directors
Compass Pathways Elects Kathleen Tregoning to Board of Directors

Image: Businesswire
Compass Pathways plc, a biotechnology firm focused on mental health innovations, has elected Kathleen Tregoning to its Board of Directors. Tregoning, with extensive experience in biopharmaceuticals, will contribute to the company's mission to deliver new treatment options for treatment-resistant depression, particularly through its investigational COMP360 treatment.
- 01Kathleen Tregoning will serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee.
- 02She previously held significant roles at Cerevel Therapeutics and Sanofi, guiding growth and overseeing public policy.
- 03Compass Pathways is advancing its COMP360 psilocybin treatment, which has received Breakthrough Therapy designation from the FDA.
- 04The company is currently in the process of submitting a new drug application (NDA) for COMP360.
- 05Tregoning emphasizes the importance of patient engagement and education as Compass moves towards commercialization.
Advertisement
In-Article Ad
Compass Pathways plc, a biotechnology company committed to enhancing mental health treatment access, has appointed Kathleen Tregoning to its Board of Directors during its annual general meeting. Tregoning, who will serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee, brings a wealth of experience from her previous roles at Cerevel Therapeutics and Sanofi, where she oversaw corporate strategy and public policy. With Compass Pathways advancing its investigational COMP360 psilocybin treatment for treatment-resistant depression, Tregoning's expertise is expected to be invaluable as the company aims for FDA approval. CEO Kabir Nath highlighted the significance of her experience in external engagement and patient access as Compass prepares for regulatory review. Tregoning expressed her commitment to supporting the company's mission, emphasizing the critical need for new mental health treatment options. Compass Pathways, headquartered in London with a U.S. office in New York, is pioneering innovative approaches to mental health care, aiming to provide effective solutions for those underserved by existing treatments.
Advertisement
In-Article Ad
The appointment of Tregoning is expected to enhance Compass Pathways' efforts to bring innovative mental health treatments to market, directly impacting patients with treatment-resistant depression.
Advertisement
In-Article Ad
Reader Poll
How important do you think new mental health treatment options are?
Connecting to poll...
More about Compass Pathways plc
Read the original article
Visit the source for the complete story.






